Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC).

@article{Peeters2007SerumII,
  title={Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC).},
  author={Petra H. M. Peeters and Annekatrin Lukanova and Naomi E. Allen and Franco Berrino and Timothy J Key and Laure Dossus and Sabina Rinaldi and Carla H van Gils and H. Bas Bueno-de-Mesquita and H. B{\"o}ing and Mandy Schulz and Jenny Chang-Claude and Jakob P Linseisen and Salvatore Panico and Carlotta Sacerdote and Domenico Palli and Rosario Tumino and Antonia Trichopoulou and Dimitrios Trichopolos and Christina Bamia and N Guerrini de Larra{\~n}aga and Eva Ardanaz and Guillem Pera and Jos{\'e} Ram{\'o}n Quir{\'o}s and Carmen Mart{\'i}nez-Garc{\'i}a and Carmen Navarro and Sheila Anne Bingham and Kay-Tee Khaw and Françoise Clavel and Anne Tjonneland and Anja Olsen and Kim Overvad and Mette Skytte Tetsche and Eiliv Lund and Eva A Lundin and G{\"o}ran GB Berglund and Elio Riboli and Rudolf Kaaks},
  journal={Endocrine-related cancer},
  year={2007},
  volume={14 1},
  pages={81-90}
}
We set out to study the relationship between circulating levels of IGF-I and its major binding protein (IGFBP-3) in relation to ovarian cancer risk. We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. Levels of IGF-I and IGFBP-3 were measured in prediagnostic serum samples of 214 women who subsequently developed ovarian cancer, and 388 matched control subjects. Conditional logistic regression models were used to estimate relative… CONTINUE READING